Shuttle Pharmaceuticals Inc(SHPH) 2023 Earnings Summary
Bullish Points:
1. In September 2022, the company completed its initial public offering, generating net proceeds of $10,022,193.
2. In January 2023, the company entered into a Convertible Note agreement with a principal value of $4,300,000, providing $3,590,000 in net proceeds.
3. The company's existing cash resources are expected to provide sufficient funds for operations through the second half of 2024.
4. Cash and cash equivalents as of March 31, 2023: $7,169,268.
5. Marketable securities as of March 31, 2023: $2,991,771.
6. Research and development expenses include a $1,500,000 project with TCG GreenChem, with two milestone payments made so far.
7. The increase in R&D spending is primarily due to funding received from the Company's public offering in Q4 of fiscal 2022 and the convertible note issued during the period ended March 31, 2023.
8. Total current assets were $10,371,898 and total current liabilities were $1,388,354, resulting in working capital of $8,983,544 as of March 31, 2023.
Bearish Points:
1. Net loss for the three months ended March 31, 2023: $975,097.
2. Total operating expenses for the three months ended March 31, 2023: $1,544,780.
3. Derivative liabilities as of March 31, 2023: $1,390,000.
4. Research and development expense increased by 242% to $1,010,808 for the three months ended March 31, 2023, compared to $295,915 for the same period in 2022.
5. General and Administrative expenses increased by $152,579 or 1,108% in Q1 2023 compared to Q1 2022.
6. Legal and Professional expenses increased by $38,912 or 12% in Q1 2023 compared to Q1 2022.
7. Material weaknesses were identified in the company's internal controls over financial reporting related to accounting policy, documentation, and financial statement close process and financial reporting reviews.
8. Management concluded that disclosure controls and procedures were not effective as of March 31, 2023, due to material weaknesses in internal controls over financial reporting.
In summary, Shuttle Pharmaceuticals Inc (SHPH) has shown strong financial growth through its initial public offering and convertible note agreement, resulting in increased cash resources and working capital. However, the company has also experienced a net loss, increased operating expenses, and identified material weaknesses in its internal controls over financial reporting. For more information, you can read the original text of Shuttle Pharmaceuticals Inc's financial report: https://www.sec.gov/Archives/edgar/data/1757499/000149315223019138/form10-q.htm
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
